BeOne Medicines Executive and Leadership Team

Anand Reddi, the Vice President, Chief of Staff To the Chairman and Chief Executive Officer at BeOne Medicines, manages the strategic agenda for the executive leadership team. Reddi facilitates high-level decision-making processes, ensuring that the vision of the Chairman and Chief Executive Officer translates into actionable operational goals. By bridging the gap between executive strategy and departmental execution, the Vice President, Chief of Staff To the Chairman and Chief Executive Officer maintains alignment across all global biotechnology initiatives. This leadership role involves preparing critical briefings and coordinating stakeholder engagement to support the company's expansion into new therapeutic areas. Anand Reddi monitors the progress of key corporate objectives, providing the necessary support to ensure that research and development efforts remain focused on patient-centric outcomes. Through meticulous planning and strategic oversight, the Vice President, Chief of Staff To the Chairman and Chief Executive Officer strengthens the company's market position and ensures long-term sustainability in the competitive pharmaceutical sector.

Xiaobin Wu, the President & Chief Operating Officer at BeOne Medicines, directs the global operational strategy to ensure the efficient delivery of next-generation cancer treatments. Wu oversees the entire clinical development lifecycle, from initial research phases to large-scale manufacturing and distribution. By optimizing operational workflows, the President & Chief Operating Officer ensures that the company meets its ambitious goals for speed and affordability in patient care. This leadership role involves managing complex supply chains and coordinating with regional teams to expand the reach of life-saving therapies across international borders. Xiaobin Wu maintains a focus on operational excellence, driving the company's commitment to equity in healthcare access. Through strategic oversight of daily business activities, the President & Chief Operating Officer supports the growth of the organization while maintaining the highest standards of quality. Ultimately, Wu ensures that the company's operational capabilities remain robust enough to address the urgent needs of cancer patients worldwide.

Yiwei Yu, the Chief of Staff To Global President and Chief Operating Officer at BeOne Medicines, manages the operational priorities for the global leadership team. Yu coordinates the execution of strategic initiatives, ensuring that the Global President and Chief Operating Officer receives the necessary data and support to drive company-wide performance. By facilitating communication across international departments, the Chief of Staff To Global President and Chief Operating Officer ensures that research and manufacturing teams remain synchronized with the company's overarching mission. This leadership role involves analyzing operational metrics to identify opportunities for increased efficiency in the development of cancer treatments. Yiwei Yu monitors the progress of global projects, providing the oversight required to maintain momentum in competitive markets. Through proactive management of executive workflows, the Chief of Staff To Global President and Chief Operating Officer strengthens the company's ability to deliver innovative therapies to patients worldwide, ensuring that operational goals align with the commitment to speed and affordability.

Danielle Abatemarco, the Chief of Staff at BeOne Medicines, coordinates internal operations to accelerate the development of next-generation cancer treatments. Abatemarco manages cross-functional workflows, ensuring that research teams align with the broader corporate mission of delivering affordable therapies to patients globally. By streamlining communication between departments, the Chief of Staff optimizes resource allocation for high-priority biotechnology projects. This leadership role involves monitoring project milestones and facilitating decision-making processes that impact the speed of clinical advancements. Danielle Abatemarco maintains rigorous oversight of operational efficiency, which directly supports the company's goal of expanding access to life-saving care. Through proactive management of internal initiatives, the Chief of Staff fosters a culture of accountability and precision. Ultimately, Abatemarco drives the organizational agility required to maintain a competitive edge in the global pharmaceutical landscape while ensuring that every internal process serves the ultimate objective of improving patient outcomes.

Marcello Damiani, the Chief Technology Officer at BeOne Medicines, architects the digital infrastructure necessary for cutting-edge cancer research and therapy development. Damiani oversees the integration of advanced data analytics and computational tools to enhance the precision of pharmaceutical manufacturing processes. By implementing scalable technology solutions, the Chief Technology Officer enables research teams to process complex biological data with greater speed and accuracy. This leadership role involves collaborating with global partners to ensure that technological platforms support the company's mission of equitable treatment access. Marcello Damiani directs the deployment of secure, high-performance systems that protect intellectual property while facilitating international collaboration. Through the strategic application of emerging technologies, the Chief Technology Officer improves the efficiency of the entire drug discovery pipeline. Ultimately, Damiani secures the technological foundation that allows the company to push the boundaries of modern medicine and deliver innovative solutions to patients across diverse geographic markets.

Wendy Shagena, the Manager, Quality Assurance & Chief Marketing Officer, Vendor Management at BeOne Medicines, enforces strict quality standards while overseeing the strategic management of external partnerships. Shagena ensures that all vendors align with the company's rigorous requirements for manufacturing next-generation cancer therapies. By auditing supplier performance and managing contractual relationships, the Manager, Quality Assurance & Chief Marketing Officer, Vendor Management mitigates operational risks and guarantees the integrity of the clinical supply chain. This leadership role involves integrating quality control protocols into the marketing and vendor selection processes to ensure that every component of the treatment delivery system meets global safety standards. Wendy Shagena drives the development of vendor strategies that prioritize affordability and reliability, directly supporting the company's mission to provide equitable care. Through consistent monitoring and process improvement, the Manager, Quality Assurance & Chief Marketing Officer, Vendor Management maintains the high quality of products that patients rely on for life-saving outcomes.

Shiqi Chen, the Specialist, Chief Marketing Officer Site Management, Clinical Supply Chain at BeOne Medicines, manages the logistical coordination of clinical trial sites to ensure the timely delivery of experimental therapies. Chen oversees the supply chain operations that support the company's research initiatives, ensuring that clinical sites have the necessary resources to conduct trials effectively. By optimizing site management processes, the Specialist, Chief Marketing Officer Site Management, Clinical Supply Chain improves the speed and reliability of the drug development pipeline. This leadership role involves coordinating with clinical teams to ensure that supply chain logistics align with the company's commitment to equitable patient access. Shiqi Chen monitors inventory levels and distribution channels, preventing delays that could impact the progress of life-saving research. Through meticulous attention to supply chain details, the Specialist, Chief Marketing Officer Site Management, Clinical Supply Chain supports the company's mission to improve cancer outcomes by ensuring that clinical trials operate with maximum efficiency and precision.

Nancy Lam, the Vice President, Global Product & Team Leader & Solid Tumors Chief of Staff at BeOne Medicines, directs the development strategy for solid tumor therapies. Lam oversees the cross-functional teams responsible for bringing new cancer treatments from the laboratory to clinical application. By managing the product lifecycle, the Vice President, Global Product & Team Leader & Solid Tumors Chief of Staff ensures that research efforts remain focused on addressing the most critical needs of patients. This leadership role involves coordinating with medical and scientific experts to refine therapeutic approaches and accelerate the pace of innovation. Nancy Lam monitors the progress of solid tumor programs, providing the strategic guidance necessary to overcome development challenges. Through the effective management of global product teams, the Vice President, Global Product & Team Leader & Solid Tumors Chief of Staff drives the company's mission to provide accessible and effective cancer care, ensuring that every therapeutic candidate receives the resources required for successful advancement.

Chun Yi, the Global Statistics & Data Science Chief of Staff at BeOne Medicines, manages the analytical operations that underpin the company's clinical research. Yi oversees the integration of statistical methodologies and data science practices to validate the efficacy of next-generation cancer treatments. By coordinating the efforts of data scientists and statisticians, the Global Statistics & Data Science Chief of Staff ensures that research findings meet the highest standards of scientific rigor. This leadership role involves facilitating the use of advanced data models to predict patient outcomes and optimize clinical trial designs. Chun Yi monitors the quality of data collection and analysis, providing the insights necessary for informed decision-making across the organization. Through the strategic management of data science resources, the Global Statistics & Data Science Chief of Staff supports the company's commitment to evidence-based medicine, ensuring that every therapy developed is backed by robust statistical evidence and a clear understanding of its impact on patient health.

Mark Lanasa, the Senior Vice President, Chief Medical Officer, Solid Tumors at BeOne Medicines, leads the clinical strategy for the company's oncology portfolio. Lanasa oversees the medical research and clinical trial programs focused on solid tumors, ensuring that all therapies meet the highest standards of safety and efficacy. By providing medical expertise to the development teams, the Senior Vice President, Chief Medical Officer, Solid Tumors guides the company's efforts to create innovative treatments that address unmet patient needs. This leadership role involves collaborating with regulatory bodies and medical professionals to ensure that clinical data supports the successful approval and adoption of new therapies. Mark Lanasa monitors the medical landscape to identify emerging trends in cancer care, allowing the company to adapt its research strategy accordingly. Through the strategic oversight of clinical programs, the Senior Vice President, Chief Medical Officer, Solid Tumors drives the company's mission to improve outcomes for cancer patients by delivering high-quality, life-saving medical solutions.